Expression of LIN28A/B and Let-7 miRNAs in canine mammary carcinomas

Raquel Lozano Guilharducci1 Pedro Luiz Porfirio Xavier1 Juliano Coelho da Silveira2
Yonara de Gouveia Cordeiro1 Luiz Roberto Biondi1
Ricardo de Francisco Strefezzi1 Heidge Fukumasu1*

1Laboratório de Oncologia Comparada e Translacional, Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos (FZEA), Universidade de São Paulo (USP), 13635-900, Pirassununga, SP, Brasil. E-mail: fukumasu@usp.br. *Corresponding author.
2Laboratório de Morfofisiologia Molecular e Desenvolvimento, Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos (FZEA), Universidade de São Paulo (USP), Pirassununga, SP, Brasil.
3Faculdade de Medicina Veterinária da Universidade Metropolitana de Santos (UNIMES), Santos, SP, Brasil.

ABSTRACT: LIN28 is a RNA-binding protein including two highly conserved homologues, LIN28A and LIN28B. Proto-oncogenes such as LIN28A and LIN28B are generally targeted by the let-7 miRNAs in different types of human cancers. Here, we determined the expression of LIN28A in canine mammary tumor samples and the LIN28/let-7 pathway in canine mammary cell lines. In those cell lines, we identified a functional LIN28/let-7 pathway which exhibited high expression of let-7 members and low expression of its targets, including LIN28A and LIN28B. However, the mammary carcinoma tissue samples showed a frequent expression of LIN28A being expressed mainly in the epithelial cells. No association was observed between LIN28A expression and histopathological classification and grade, TNM and survival time. Our results suggested a possible role of the LIN28A protein in the development of canine mammary carcinomas due to the high frequency observed in the tumor samples (28 of 32). The in vitro experiments suggested that the LIN28/let-7 pathway is active in the tumor cells evaluated. However, more studies are necessary to elucidate the exact role of LIN28A/let-7 pathway in canine mammary carcinomas.

Key words: canine mammary carcinomas, LIN28, let-7, veterinary oncology.

INTRODUCTION

The LIN28A and LIN28B genes have been studied in several types of human cancer such as breast (PISKOUNOVA et al., 2011; XIONG et al., 2017), colon (KING et al., 2011), gastric (HU et al., 2014), ovarian (LU et al., 2012) and prostate cancer (ALBINO et al., 2016). These genes are frequently found with high expression in these tumors exhibiting a key role in transformation, progression, and malignancy (HAMANO et al., 2012; ZHOU et al., 2013). Furthermore, high expression of LIN28A/B in human malignant tumors is related to Epithelial-Mesenchymal Transition (EMT) and the Cancer Stem Cell (CSCs) phenotype (LIU et al., 2013; VISWANATHAN & DALEY, 2010) being associated to high rate of metastasis, relapse, and reduced survival time (WANG et al., 2015).
The family of let-7 miRNAs plays an important function during carcinogenesis acting as a tumor suppressor and regulating the expression of a large number of oncogenes including LIN28A/B (CAI et al., 2013; KOLENDA et al., 2014; LV et al., 2012; THORNTON & GREGORY, 2012). Furthermore, the presence of let-7 is related to cellular differentiation, proliferation and self-renewal developing a key role in the regulation of genes like c-MYC, RAS and HMGA2 (SAKURAI et al., 2012; WANG et al., 2012). Thus, let-7 miRNAs are post-transcriptionally downregulated in various types of cancer such as pancreatic cancer, ovarian cancer, prostate cancer, breast cancer and melanoma (WANG et al., 2015) mostly targeted by LIN28A/B in a double-negative feedback, through distinct mechanisms.

Only few studies have addressed the LIN28/let-7 pathway in canine cancers. STERENCZAK et al. (2014) observed a small frequency of LIN28 gene expression in oral squamous cell carcinoma (OSCC). In the same tissues, let-7 expression was constant and higher in the OSCC samples in comparison with non-neoplastic control samples indicating a possible LIN28 regulation mediated by let-7, in contrast to studies in human cancer (STERENCZAK et al., 2014). Therefore, more detail studies need to be performed to elucidate the role of LIN28/let-7 pathway in canine cancer in general.

Here, we evaluated the presence and frequency of LIN28A protein in canine mammary carcinomas, as well as the mRNA expression of LIN28A/B proto-oncogenes and the let-7 miRNA family members in cell lines isolated from canine mammary carcinomas to observe the presence of the LIN28A/let-7 pathway in the canine mammary cancer cells.

**MATERIALS AND METHODS**

**Cell lines**

Two cell lines were used in this study: M5 and M25, previously isolated from canine mammary tumors and characterized regarding to morphology, cytoskeleton filaments markers and malignant potential. Both lines present spindle cell shape and cytokeratin, vimentin and α-smooth actin expression, characteristic immunomarkers of myoepithelial-like cells. Furthermore, these cell lines were positive for invasion and tumor sphere assays. Molecular validation of cell lines was also performed previously (CORDEIRO et al., 2018; XAVIER et al., 2019). M5 and M25 cells were maintained in 75 cm² flasks at 37 °C and 5% CO₂ with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F12) supplemented with 10% fetal bovine serum and 1% antibiotic/antimyotic. Passageing was performed when cells were 85% confluent. Culture evolution was evaluated daily by optical microscopy (Axio Vert A1, Zeiss, Germany). All reagents used for cell culture were purchased from Thermo Fisher Scientific, USA.

**RNA extraction, cDNA synthesis and Real Time PCR**

Gene expression of LIN28A, LIN28B, let-7a, let-7b, let-7c, let-7e, and let-7g miRNAs was evaluated by qPCR. The total RNA of M5 and M25 cell lines was extracted using TRIzol Reagent (Thermo Fisher Scientific, USA), following the manufacturer’s recommendation. RNA samples were quantified and the 260/280 and 260/230 ratio were determined by NanoDrop 2000™ (Thermo Fisher Scientific, USA). Reverse transcription to obtain cDNA was performed using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, USA), according to manufacturer’s protocol. The reverse transcription of the miRNAs was performed using the miScript II RT kit (QIAGEN, Germany). Specific primers were designed using Primer3 Plus program (UNTERGASSER et al., 2007). LIN28A/B qPCR reactions were carried out using Fast SYBR Green Master Mix (Thermo Fisher Scientific, USA). Conditions for quantitative qPCR were as follows: 95 °C for 20 seconds; 40 cycles at 95 °C for 3 seconds for denaturation, 60 °C for 30 seconds for anneal/extend; melt curve analysis was performed at 95 °C for 15 seconds and 60 °C for 60 seconds. Let-7 members family qPCR reactions were carried out using miScript SYBR green PCR kit (QIAGEN, Germany). Conditions for qPCR were as follows: 95 °C for 15 minutes; 40 cycles at 94 °C for 15 seconds for denaturation, 55 °C for 30 seconds for annealing, 70 °C for 30 seconds for extension. The housekeeping genes used were 18S ribosomal RNA for LIN28A/B reactions and the RNT43 snoRNA and Hm/Ms/Rnt-1 snRNA for let-7 reactions. The analysis of relative gene expression data was performed according to the ΔΔCt method (LIVAK & SCHMITTGEN, 2001). The experiment was performed using three biological triplicates and analyzed in technical duplicates.

**Prediction of let-7 targets**

The target prediction of the let-7 family was performed using in silico analyses by the database miRTarBase (CHOU et al., 2018). This tool provides experimentally validated target genes of specific miRNAs; however, this database is designed for
human miRNAs. Thus, to validate if the genes can also be target by let-7 in canine species, the 3’UTR homology of these genes in both species was evaluated using TargetScan tool (AGARWAL et al., 2015).

**Gene expression of let-7 targets by RNA-seq data analysis**

Evaluation of the expression of predicted let-7 targets was performed from the results obtained from the global analyses of gene expression from M5 and M25 cell lines. Extraction of RNA, preparation of mRNA libraries, sequencing and sequencing quality, alignments and analysis to determine FPKM are described in CORDEIRO et al., 2018. Once we obtained a high sequencing quality, each sample was aligned against the reference genome (CanFam3.1) using TopHat 2.0.9 and Bowtie 2.1.0 ENREF_11. PCR duplicates, not primary alignments and low-quality reads were removed with Sam tools and the abundance of the transcripts that aligned with the reference genome was determined using Cufflinks 2.2.1, providing the fragments per kilobase million (FPKM) values. The FPKM values for each let-7 target were analyzed.

**Tissues samples and Immunohistochemistry evaluation of LIN28A protein**

Thirty samples of formalin-fixed and paraffin-embedded tissues (FFPE) from canine mammary carcinomas attended in the Veterinary Hospital of the Metropolitan University of Santos (UNIMES), under the supervision of Prof. Dr. Luiz Roberto Biondi, were used. In addition, were included tissue samples obtained in private veterinary clinics, from which M5 and M25 cell lines were derived. All these hospitals and clinics agreed to participate in the present study according to the protocol approved by the Ethics Committee on Animal Use, University of Sao Paulo, protocol number CEUA/3094061014. Samples were classified according to histological type and tumor grading following the criteria proposed by Goldschmidt 2011 (GOLDSCHMIDT et al., 2011). The information about patient survival time and TNM tumor staging were classified according to percentage of stained cells, it varied from 0 to 3, being 0, no tumor cell stained; 1, 10 – 50% of tumor cells stained, and 3, more than 50% of tumor cells stained. The final score was obtained by multiplying the intensity score with the percentage score, resulting in values from 0 to 9 (HSU et al., 2015).

**Statistical analysis**

Statistical analysis and graphs were made with GraphPad Prism® 6.0 Software (San Diego, CA, USA). The comparison between the let-7 members expression in the two cell lines was performed by Kruskal-Wallis test. Association between LIN28A score and histopathological type was performed by ANOVA. The correlations between LIN28A immunostaining score with histological grading and TNM staging were performed by Spearman correlation. The relation between LIN28A score and patients’ survival time was assessed using the Kaplan-Meier curve. Significant statistical differences were considered when P < 0.05.

**RESULTS**

**Gene expression of let-7 miRNAs family in cell lines**

In order to verify the expression levels of let-7 miRNAs in M5 and M25 myoepithelial-like cells, we performed qPCR analysis. Let-7a, let-7b, let-7c, let-7e, and let-7g miRNAs were highly expressed in both cell lines, with no significant statistical difference between M5 and M25 cell lines (Table 1).
However, we observed differences regarding the let-7 expression in each cell line, where the let-7g is the less expressed both in the M5 and M25 cell lines (P < 0.05; Figure 1).

**Gene expression of let-7 targets evaluated by RNA-seq**

Besides LIN28A/B, let-7 miRNAs have several other targets described (BÜSSING et al, 2008). First, we performed an in silico analysis using MirTarBase version 7 algorithm that predicted 126 experimentally validated target genes of let-7 miRNA family. From these 126 targets, 65 genes showed homology at the seed region between the human and canine species, as observed using TargetScan version 7.2. Finally, the RNA-Seq data confirmed low expression of some let-7 target genes in M5 and M25 cell lines. From 65 targets, 10 genes exhibited low expression with FPKM values equal to or close to zero, including IL10, PRDM1, KLK10, MYCN, FASLG, IGF1, IGF2BP1 and TRIM71 (Table 2). These results suggested that the LIN28/let-7 pathway is potentially functional in M5 and M25 cell lines.

| Gene  | M5           | M25           |
|-------|--------------|---------------|
| CT    | 10.95 ± 0.35 | 10.65 ± 0.23  |
| CT let-7a | 18.88 ± 0.44 | 18.23 ± 0.22  |
| 2ΔΔCT let-7a | 1.00 ± 0.06 | 1.31 ± 0.41   |
| CT let-7b | 19.97 ± 1.01 | 18.72 ± 0.23  |
| 2ΔΔCT let-7b | 1.15 ± 0.64 | 1.93 ± 0.29   |
| CT let-7c | 18.49 ± 0.56 | 18.10 ± 0.15  |
| 2ΔΔCT let-7c | 1.01 ± 0.18 | 1.07 ± 0.27   |
| CT let-7e | 18.60 ± 0.56 | 18.14 ± 0.05  |
| 2ΔΔCT let-7e | 1.00 ± 0.16 | 1.12 ± 0.21   |
| CT let-7g | 22.47 ± 0.28 | 22.63 ± 0.04  |
| 2ΔΔCT let-7g | 1.38 ± 0.08 | 1.00 ± 0.13   |

**Figure 1** - Comparison between Let-7 oncomiRs expression levels evaluated in M5 (A) and M25 (B) cell lines (*P < 0.05 ** P < 0.01 - one-way ANOVA followed by tukey’s multiple comparison test). We observed a significant difference expression of Let-7 members in both cell lines.
Expression of LIN28A/B and Let-7 miRNAs in canine mammary carcinomas.

Table 2 - From the 65 Let-7-target genes, 10 genes exhibited very low expression with FPKM (fragments per kilobase million) values equal to or close to zero.

| miRTarBase ID | miRNA   | Target Gene | Ensemble code (Canine Species) | FPKM (M5) | FPKM (M25) |
|---------------|---------|-------------|--------------------------------|-----------|------------|
| MIRT054365    | hsa-let-7c-5p | IL10        | ENSCAFG00000011443            | 0.31      | 0          |
| MIRT005514    | hsa-let-7f-5p | PDM1        | ENSCAFG00000003694            | 0         | 0          |
| MIRT000455    | hsa-let-7f-5p | KLK10       | ENSCAFG00000029529            | 0         | 0          |
| MIRT032100    | hsa-let-7e-5p | MYCN        | ENSCAFG00000003715            | 0         | 0          |
| MIRT731263    | hsa-let-7e-5p | FASLG       | ENSCAFG00000014678            | 0         | 0          |
| MIRT054579    | hsa-let-7e-5p | IGF1        | ENSCAFG00000007304            | 0.57      | 0.34       |
| MIRT006055    | hsa-let-7a-5p | IGF2BP1     | ENSCAFG00000016907            | 0.61      | 0          |
| MIRT003834    | hsa-let-7a-5p | LIN28A      | ENSCAFG00000012488            | 0         | 0          |
| MIRT02077     | hsa-let-7a-5p | LIN28B      | ENSCAFG0000003598            | 0         | 0          |
| MIRT002077    | hsa-let-7a-5p | TRIM71      | ENSCAFG00000025466            | 0.31      | 0.85       |

LIN28A protein expression in canine mammary carcinoma tissues

In order to evaluate the presence of LIN28A protein expression in canine mammary carcinoma, 32 samples of different histopathological types were analyzed by immunohistochemistry. The LIN28A protein expression was observed in 28 of 32 mammary carcinomas samples. Positive samples exhibited final staining score ranging between 1 and 9 according to their intensity and percentage of stained cells (HSU et al., 2015). Samples 5952, 12709, 16786 and 17773 were negative for LIN28A presenting final score 0 (Table 3). The LIN28A expression was observed in the nucleus and/or cytoplasm of parenchymal cells, predominantly in epithelial cells. The stromal tissue showed less or no expression of LIN28A. In addition, 23 samples exhibited variable expression of LIN28A in myoepithelial cells. LIN28A expression was also frequently observed in endothelial cells. No significant statistical correlation was observed between staining score and histopathological type, histological grading, TNM staging and survival time. (Table 3 and figure 2).

DISCUSSION

In the present study, we evaluated the expression of five members of the let-7 miRNAs family in two myoepithelial-like cell lines isolated from canine mammary carcinomas. The results showed that all let-7 members were highly expressed in both cell lines. In addition, we observed low expression of let-7 targets genes including the homologues LIN28A and LIN28B, suggesting that the LIN28A/let-7 pathway may be functional in these canine mammary cancer cell lines. However, in contrast to the results reported in cell lines, we showed a frequent and heterogeneous expression of LIN28A protein in different histopathological canine mammary carcinomas tissues by immunohistochemistry.

In mammals, LIN28A/B develop a key role in many biological processes including stem cell differentiation, cell proliferation and glucose metabolism (CHANG & DALEY, 2013; ZHANG et al., 2016). In human tumors, LIN28 expression is generally upregulated, correlating with advanced disease and poor prognosis for many cancer subtypes (WANG et al., 2015). Conversely, this is the first description of LIN28 protein expression in canine mammary cancers. We determined the presence of the LIN28A protein in tissue samples from canine mammary carcinomas. The protein was expressed in 87.5% of the samples, mainly in the epithelial cancerous cells. However, the myoepithelial cells and other stromal cells showed modest or absent expression of LIN28A protein. Some studies in humans described the expression of LIN28A and LIN28B mainly in cancer cells presenting a mesenchymal phenotype, since they are directly associated with epithelial-mesenchymal transition.
Table 3 - Evaluation of LIN28A expression in 32 samples of canine mammary carcinomas. LIN28A protein expression was observed in 28 of 32 canine mammary carcinoma samples, exhibiting final score staining ranging from 1 to 9. Samples exhibiting final score 0 were considered negative.

| Histopathological type (GOLDSCMIDT et al., 2011) | Samples | Intensity | Percentage | Final Score | Stroma | Myoepithelial cells | Endothelial cells |
|-------------------------------------------------|---------|-----------|------------|-------------|--------|---------------------|------------------|
| Tubular                                         | 12318   | 1         | 3          | 3           | Yes    | Yes                 | Yes              |
| Tubular                                         | 17695   | 1         | 2          | 2           | No     | No                  | No               |
| Tubular                                         | 17704   | 1         | 2          | 2           | Yes    | No                  | No               |
| Tubular                                         | 17939   | 1         | 1          | 1           | No     | No                  | Yes              |
| Tubular                                         | 18690   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Tubular                                         | 18997   | 2         | 2          | 4           | Yes    | Yes                 | Yes              |
| Tubulopapillary                                 | 5952    | 0         | 0          | 0           | No     | No                  | No               |
| Tubulopapillary                                 | 16766   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Tubulopapillary                                 | 17577   | 2         | 1          | 2           | No     | No                  | Yes              |
| Tubulopapillary                                 | 17629   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Tubulopapillary                                 | 17773   | 0         | 0          | 0           | No     | No                  | Yes              |
| Tubulopapillary                                 | 18719   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Complex                                         | 16461   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Complex                                         | 16770   | 3         | 3          | 9           | Yes    | Yes                 | Yes              |
| Complex                                         | 16786   | 0         | 0          | 0           | No     | No                  | Yes              |
| Complex                                         | 17621   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Complex                                         | 17641   | 2         | 2          | 4           | Yes    | Yes                 | Yes              |
| Complex                                         | 18127   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Complex                                         | 18558   | 2         | 2          | 4           | Yes    | Yes                 | Yes              |
| Mixed                                           | 16160   | 3         | 3          | 9           | Yes    | Yes                 | Yes              |
| Mixed                                           | 17564   | 1         | 3          | 4           | Yes    | Yes                 | Yes              |
| Mixed                                           | 17630   | 1         | 2          | 2           | Yes    | No                  | Yes              |
| Mixed                                           | 18141   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 18341   | 1         | 1          | 1           | No     | Yes                 | Yes              |
| Mixed                                           | 19136   | 3         | 2          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 025/14  | 3         | 3          | 9           | Yes    | Yes                 | Yes              |
| Mixed                                           | 11025   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 005/13  | 3         | 2          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 12709   | 0         | 0          | 0           | No     | No                  | Yes              |
| Mixed                                           | 17524   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 18062   | 2         | 3          | 6           | Yes    | Yes                 | Yes              |
| Mixed                                           | 17570   | 2         | 2          | 4           | Yes    | Yes                 | Yes              |

Ciência Rural, v.52, n.10, 2022.
Expression of LIN28A/B and Let-7 miRNAs in canine mammary carcinomas.

Studies also demonstrate that LIN28A is also present in mammal epithelial cells poorly differentiated of lung, kidney, and intestine during the embryonic development but with the progression of gene differentiation is downregulated (TSIALIKAS & ROMER-SEIBERT, 2015; YANG & MOSS, 2003).

The cellular distribution of LIN28A in cancer cells has also been widely studied. It has been reported that LIN28A is predominantly present in the cytoplasm. The localization of LIN28A is probably related to its function, which inhibits the processing of let-7 precursors by Dicer in the cytoplasm (PISKOUNOV A et al., 2011). Nevertheless, it is also reported that LIN28A proteins can be reported in a lesser extent in the nucleus and nucleolus of the cells (BALZER & MOSS, 2007; CHANG & DALEY, 2013; VOGT et al., 2012).

In the present study, we also evaluated the presence of LIN28A protein expression in 87.5% of our canine mammary carcinoma samples. This result suggested that LIN28A could play a more important role in the pathogenesis of canine mammary carcinomas, including the tissues that originated the M5 and M25 cell lines (005/13 and 025/14), showed significant expression of LIN28A protein, the gene expression of both LIN28A and LIN28B were not detected in the cell lines. This could be explained by two hypotheses: 1) the tumor dissociation process and cell culture of our conditions selected myoepithelial cells. In fact, both cell lines present a myoepithelial-like phenotype, and some cells with this phenotype did not originally express the protein LIN28A in the tissues, as it was demonstrated in the LIN28A immunohistochemistry assay; 2) when cells were dissociated from the primary tumor and cultured, the cell gene expression profile changed leading to the loss of some malignancy characteristics. This can justify the high let-7 miRNAs gene expression and the downregulation of LIN28A, LIN28B and other gene targets. Taken together, these possibilities may justify why the cell lines used in this experiment did not express LIN28A and LIN28B genes.

So far, only one study about LIN28A/let-7 pathway in canine cancer could be found. STERENCZAK et al. (2014) observed that in seven tissue samples of OSCC, only one showed LIN28A expression evaluated by real-time PCR. Conversely, we observed LIN28A protein expression in 87.5% of our canine mammary carcinoma samples. This result suggested that LIN28A could play a more
relevant role in mammary carcinomas in dogs. Lastly, regard to the cell culture, STERENCHAK et al. (2014) demonstrated that the two canine OSCC cell lines expressed let-7a but did not express LIN28A, similar to what we reported in the present research. Thus, despite the previous results, the present study contributed to the identification of a possible role of LIN28 genes in canine mammary carcinomas.

CONCLUSION

In conclusion, our findings demonstrated the presence of LIN28A expression in the canine mammary cancer tissues and the probable functionality of LIN28/let-7 pathway in canine mammary carcinoma cells, with let-7 members possibly regulating the expression of its targets. Despite the results observed here, more studies are necessary to determine the role of LIN28A and LIN28B in cancer development and progression in canine species.

ACKNOWLEDGEMENTS

This study and RLG scholarship were funded by Fundação de Amparo à Pesquisa de São Paulo (FAPESP) – Proc. 2014/02493-7 and 2015/10036-8. PLPX scholarship were also funded by FAPESP – Proc. 2017/11966-4 and 2019/05778-6. The authors would like to thank the researchers Lidia Hildebrand Pulz and Thiago Henrique Moroni Vargas for the collaboration in the immunohistochemistry assay.

DECLARATION OF CONFLICT OF INTEREST

We have no conflict of interest to declare.

AUTHOR’S CONTRIBUTIONS

Conceptualization, H.F., R.L.G. and J.C.S.; Methodology, H.F., R.L.G., P.L.P.X., Y.G.C., R.F.S. and L.R.B.; Formal Analysis: H.F., R.L.G., P.L.P.X; Resources: H.F., R.F.S., and Thiago Henrique Moroni Vargas for the collaboration in the immunohistochemistry assay.

REFERENCES

AGARWAL, V. et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife, v. 4, e05005, 2015. Available from: <http://dx.doi.org/10.7554/eLife.05005.001>. Accessed: Apr. 16, 2018. doi: 10.7554/eLife.05005.

ALBINO, D. et al. Activation of the Lin28/let-7 axis by loss of ESE3/EHI promotes a tumorigenic and stem-like phenotype in prostate cancer. Cancer Research, v. 76, n. 12, p. 3629–3643, 2016. Available from: <https://doi.org/10.1158/0008-5472.CAN-15-2665>. Accessed: Apr. 13, 2018. doi: 10.1158/0008-5472.CAN-15-2665.

BALZER, E.; MOSS, E. G. Localization of the developmental timing regulator Lin28 to mRNP complexes, P-bodies and stress granules. RNA Biology, v. 4, n. 1, p. 16–25, 2007. Available from: <https://pubmed.ncbi.nlm.nih.gov/17617744/>. Accessed: Apr. 13, 2018. doi: 10.4161/ma.4.1.4364.

BÜSSING, I. et al. let-7 microRNAs in development, stem cells and cancer. Trends in Molecular Medicine, v. 14, n. 9, p. 400–409, 2008. Available from: <https://pubmed.ncbi.nlm.nih.gov/18764967/>. Accessed: Apr. 16, 2018. doi: 10.1016/j.molmed.2008.07.001.

CAIL, W. Y. et al. The Wnt- catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. Journal of Cell Science, v. 126, n. 13, p. 2877–2889, 2013. Available from: <https://pubmed.ncbi.nlm.nih.gov/23613467/>. Accessed: Apr. 14, 2018. doi: 10.1242/jcs.123810.

CHANG, N. S.; DALEY, G. Q. Lin28: Primal regulator of growth and metabolism in stem cells. Cell Stem Cell, v. 12, n. 4, p. 395–406, 2013. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652335/>. Accessed: Apr. 23, 2018. doi: 10.1016/j.stem.2013.03.005.

CHO, J. et al. LIN28A is a suppressor of ER-associated translation in embryonic stem cells. Cell, v. 151, n. 4, p. 765–777, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/23102813/>. Accessed: May 3, 2018. doi: 10.1016/j.cell.2012.10.019.

CHOU, C. H. et al. MiRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Research, v. 46, n. D1, p. D296–D302, 2018. Available from: <https://pubmed.ncbi.nlm.nih.gov/29126172/>. Accessed: Apr. 23, 2018. doi: 10.1093/nar/gkx1067.

CORDEIRO, Y. G. et al. Transcriptomic profile reveals molecular events associated to focal adhesion and invasion in canine mammary gland tumour cell lines. Veterinary and Comparative Oncology, v. 16, n. 1, p. E89–E98, 2018. Available from: <https://pubmed.ncbi.nlm.nih.gov/28834169/>. Accessed: Apr. 23, 2018. doi: 10.1111/vco.12339.

GOLDSCHMIDT, M. H. et al. Classification and grading of canine mammary tumors. Veterinary Pathology, v. 48, n. 1, p. 117–131, 2011. Available from: <https://pubmed.ncbi.nlm.nih.gov/21266722/>. Accessed: Apr. 14, 2018. doi: 10.1177/0300985810393258.

HAMANO, R. et al. High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer. British Journal of Cancer, v. 106, n. 8, p. 1415–1423, 2012. Available from: <https://www.nature.com/articles/bjc201290>. Accessed: Apr. 14, 2018. doi: 10.1038/bjc.2012.90.

HSU, K. F. et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. British Journal of Cancer, v. 113, n. 3, p. 414–424, 2015. Available from: <https://pubmed.ncbi.nlm.nih.gov/26158423/>. Accessed: Apr. 13, 2018. doi: 10.1038/bjc.2015.254.

HU, Q. et al. Lin28B is a novel prognostic marker in gastric adenocarcinoma. International Journal of Clinical and

Ciência Rural, v.52, n.10, 2022.
Expression of LIN28A/B and Let-7 miRNAs in canine mammary carcinomas.

 Experimental Pathology, v. 7, n. 8, p. 5083–5092, 2014. Available from: <https://pubmed.ncbi.nlm.nih.gov/25197381/>. Accessed: Apr. 17, 2018. PMID: 25197381; PMCID: PMC4152071.

 KING, C. E. et al. LIN28B promotes colon cancer progression and metastasis. Cancer Research, v. 71, n. 12, p. 4260–4268, 2011. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117110/>. Accessed: May 5, 2018. doi: 10.1118/0008-5472.CAN-10-4637.

 KOLENDÁ, T. et al. The mystery of let-7d - A small RNA with great power. Wspolczesna Onkologia, v. 18, n. 5, p. 293–301, 2014. Available from: <https://pubmed.ncbi.nlm.nih.gov/25477749/>. Accessed: Apr. 23, 2018. doi: 10.5114/wo.2014.44467.

 LANA, S. E. et al. Tumors of the mammary gland. In: WITTHOFER, S.J. & VAIL, D.M., Withrow & MacEwen’s Small Animal Clinical Oncology 4.ed. St. Louis: Saunders Elsevier, 2007. p.619-636.

 LIU, Y. et al. Lin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of let-7a in breast cancer cells. PLoS ONE, v. 8, n. 12, e83083, 2013. Available from: <https://pubmed.ncbi.nlm.nih.gov/24349438/>. Accessed: Apr. 15 2018. doi: 10.1371/journal.pone.0083083. (Electronic publication).

 LIVAK, K. J.; SCHMITTGEN, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods, v. 25, n. 4, p. 402–408, 2001. Available from: <https://pubmed.ncbi.nlm.nih.gov/11202117/>. Accessed: Apr. 15, 2018. doi: 10.1006/meth.2001.1262.

 LIU, L. et al. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis, v. 33, n. 11, p. 2119–2125, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/22822098/>. Accessed: May 4, 2018. doi: 10.1093/carcin/bgs243.

 LV, K. et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS ONE, v. 7, n. 7, e40008, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/22808064/>. Accessed: May. 3, 2018. doi: 10.1371/journal.pone.0040008. (Electronic publication).

 O'NEIL, L. N. TNM classification of tumors in domestic animals. 1st ed. Geneva: World Health Organization, Geneva, 1980.

 PISKOUNOVÁ, E. et al. Lin28A and Lin28B inhibit let-7 MicroRNA biogenesis by distinct mechanisms. Cell, v. 147, n. 5, p. 1066–1079, 2011. Available from: <https://pubmed.ncbi.nlm.nih.gov/22118463/>. Accessed: Apr. 13, 2018. doi: 10.1016/j.cell.2011.10.039.

 SAKURAI, M. et al. LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology, v. 131, n. 3–5, p. 101–106, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/22081076/>. Accessed: May. 3, 2018. doi: 10.1016/j.jsbmb.2011.10.007.

 STERENCZAK, K. A. et al. HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma. BMC Cancer, v. 14, n. 694, 2014. Available from: <https://pubmed.ncbi.nlm.nih.gov/25254114/>. Accessed: Apr. 14, 2018. doi: 10.1186/1471-2407-14-694. (Electronic publication).

 THORNTON, J. E.; GREGORY, R. I. How does Lin28 let-7 control development and disease? Trends in Cell Biology, v. 22, n. 9, p. 474–482, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/22784697/>. Accessed: May. 3, 2018. doi: 10.1016/j.tcb.2012.06.001.

 TSIALIKAS, J.; ROMER-SEIBERT, J. LIN28: Roles and regulation in development and beyond. Development (Cambridge), v. 142, n. 14, p. 2397–2404, 2015. Available from: <https://pubmed.ncbi.nlm.nih.gov/26199409/>. Accessed: Apr. 15, 2018. doi: 10.1242/dev.117580.

 UNTERGASSER, A. et al. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Research, v. 35, (Web Server issue):W71-4, 2007. Available from: <https://pubmed.ncbi.nlm.nih.gov/17485472/>. Accessed: Apr. 4, 2018. doi: 10.1093/nar/gkm306.

 VISWANATHAN, S. R.; DALEY, G. Q. Lin28: A microRNA regulator with a macro role. Cell, v. 140, n. 4, p. 445–449, 2010. Available from: <https://pubmed.ncbi.nlm.nih.gov/20178735/>. Accessed: Apr. 14, 2018. doi: 10.1016/j.cell.2010.02.007.

 VOHT, E. J. et al. Importance of the pluripotency factor LIN28 in the mammalian nucleus during early embryonic development. Development (Cambridge), v. 139, n. 24, p. 4514–4523, 2012. Available from: <https://pubmed.ncbi.nlm.nih.gov/23172912/>. Accessed: Apr. 24, 2018. doi: 10.1242/dev.083279.

 WANG, T. et al. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Molecular Cancer, v. 14, n. 1, p. 1–13, 2015. Available from: <https://pubmed.ncbi.nlm.nih.gov/26123544/>. Accessed: Apr. 13, 2018. doi: 10.1186/s12943-015-0402-5.

 WANG, X. et al. Regulation of let-7 and its target oncopnes (Review). Oncology Letters, v. 3, n. 5, p. 955–960, 2012. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389667/>. Accessed: May. 4, 2018. doi: 10.3892/ol.2012.609.

 XAVIER, P. L. et al. An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells. Scientific Reports, v. 9, 17363, 2019. Available from: <https://pubmed.ncbi.nlm.nih.gov/31758045/>. Accessed: Nov. 22, 2019. doi: 10.1038/s41598-019-53915-7.

 XIONG, H. et al. Oncogenic mechanisms of Lin28 in breast cancer: New functions and therapeutic opportunities. Oncotarget, v. 8, n. 15, p. 25721–25735, 2017. Available from: <https://pubmed.ncbi.nlm.nih.gov/22081076/>. Accessed: Apr. 17, 2018. doi: 10.3892/ol.2012.609.

 YANG, D. H.; MOSS, E. G. Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. Gene Expression Patterns, v. 3, n. 6, p. 719–726, 2003. Available from: <https://pubmed.ncbi.nlm.nih.gov/14643679/>. Accessed: Apr. 20, 2018. doi: 10.1016/s12943-015-0402-5.

 ZHANG, J. et al. LIN28 Regulates Stem Cell Metabolism and Conversion to Primed Pluripotency. Cell Stem Cell, v. 19, n. 1, p. 66–80, 2016. Available from: <https://pubmed.ncbi.nlm.nih.gov/27320042/>. Accessed: Apr. 13, 2018. doi: 10.1016/j.stem.2016.05.009.

 Ciência Rural, v.52, n.10, 2022.
ZHOU, J. et al. LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. *International Journal of Biochemistry and Cell Biology*, v. 45, n. 5, p. 973–978, 2013. Available from: <https://pubmed.ncbi.nlm.nih.gov/23420006/>. Accessed: Apr. 17, 2018. doi: 10.1016/j.biocel.2013.02.006.